A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01
Status:
Not yet recruiting
Trial end date:
2027-03-30
Target enrollment:
Participant gender:
Summary
This is a seamless Phase 1/2 study consisting of two components. Phase 1 component is a
dose-escalation, single arm, open label study in 10 patients to evaluate the safety and
tolerability of KRC 01. Phase 2 component is a randomized, open label, controlled,
multi-center study in 60 patients to evaluate the preliminary antitumor effect of KRC-01 in
combination with CRT.